摘要
目的:观察清化消瘀方对糖尿病合并粥样动脉硬化患者糖基化过程的影响。方法:60例糖尿病合并粥样动脉硬化患者随机分为治疗组30例(清化消瘀方加西药常规治疗),对照组30例(西药常规治疗),疗程4周,治疗前后测定血清糖基化终产物(AGEs)、hs-CRP、IL-6、TNF-α值,并取正常组20例予以对照。结果:治疗前治疗组血清AGEs(64.46±12.10)U/ml、hs-CRP(5.47±5.96)mg/L、IL-6(2.53±0.57)mg/L、TNF-α(2.31±0.67)μg/L,与对照组水平相当,与正常对照组比较均明显升高(P<0.05),而治疗后治疗组血清AGEs(37.3±5.75)U/ml、hs-CRP(1.24±0.57)mg/L、IL-6(2.19±0.63)mg/L、TNF-α(1.96±0.42)μg/L均明显降低(P<0.05),与正常对照组比较差异无统计学意义(P>0.05)。结论:糖尿病合并动脉粥样硬化患者由于糖基化过程导致糖基化终产物含量增高,清化消瘀方能阻断这一进程,降低其含量,从而抑制糖尿病动脉粥样硬化的形成和发展。
Objective: To observe the effect of Qinghuaxiaoyu Decoction on advanced glycation end products of diabetic merging arteriosclerosis.Methods: 60 patients with diabetic merging arteriosclerosis were randomoly divided into 2 groups,control group(n=30) was treated with Metformin Hydrochloride Tablets;treatment group(n=30) was treated with Metformin Hydrochioride Tablets and Qinghuaxiaoyu Decoction.Course of treatment was 4 weeks.AGEs,hs-CRP,IL-6,TNF-α were determined before and after treatment.Results: AGEs,hs-CRP,IL-6,TNF-α were increased obviously in both groups before treatment.AGEs,hs-CRP,IL-6,TNF-α were decreased obviously in treatment group after treatment.Conclusion: Qinghuaxiaoyu Decoction has steady and tried effect on diabetic merging arteriosclerosis,the possible mechanism is decreasing advanced glycation end products.
出处
《中国医药导报》
CAS
2011年第13期64-66,共3页
China Medical Herald
基金
2009年深圳市科技计划项目(项目名称:清化消瘀方对糖基化及其介导炎症反应影响的研究
项目编号:200903215)
关键词
清化消瘀方
糖尿病
动脉粥样硬化
糖基化终产物
炎症介质
Qinghuaxiaoyu Decoction
Diabetes
Arteriosclerosis
Advanced glycation end products
Mediators of inflammation